Montreal, Quebec--(Newsfile Corp. - June 25, 2024) - Blue Thunder Mining Inc. (TSXV: BLUE) ("Blue Thunder" or the "Company") announces that Alain Lévesque will be joining the Company's management team as CFO effective June 25, 2024, replacing Robert Boisjoli who will be resigning his position as CFO effective the same date in order to devote his full attention to other business interests. Mr. Lévesque has 20 years of experience in the field of financial reporting and the management of corporations includin ...

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Medallion Financial Corp. (NASDAQ: MFIN) (“Medallion” or the “Company”) today announced that independent proxy advisory firm Glass, Lewis & Co., LLC (“Glass Lewis”) has recommended that Medallion shareholders vote on the BLUE proxy card “FOR” ONLY the candidates nominated by the Board of Directors, Robert M. Meyer and David L. Rudnick and “FOR” the advisory vote on the compensation of the Company’s named executive officers in connection with the Company’s 2024 Ann ...

Montreal, Quebec--(Newsfile Corp. - June 4, 2024) - Blue Thunder Mining Inc. (TSXV: BLUE) ("Blue Thunder" or the "Company") announces that as of its Annual General Meeting to be held on June 6, 2024, and subject to approval at that meeting, the Company will change its name to Orbec Gold Mines Inc. ("Orbec"). The ticker will remain "BLUE" for simplicity and ease of trading as well as for legacy reasons. In addition, the Company is relocating its headquarters to 2000 rue de l'Éclipse, Suite 500, Brossard, Qu ...

2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a PartnerPost thisDr. Jones-Burton brings to 2Flo Ventures nearly two decades of experience in the biopharmaceutical industry leading clinical development of multiple medicines across various therapeutic areas. At Chinook Therapeutics, she advanced the pipeline as Senior VP of Product Development and Strategy, leading to a $3.2 billion acquisition by Novartis. Previously, she was VP of Global Clinical Deve ...

NEW YORK, May 30, 2024 /PRNewswire/ -- Blue Owl Capital Inc. ("Blue Owl") (NYSE: OWL) today announced the pricing of the offering of $250,000,000 of 6.250% Senior Notes due 2034 (the "notes") by Blue Owl Finance LLC, its indirect subsidiary, at an issue price of 100.355%, plus accrued interest, if any, from April 18, 2024. The notes are being offered as additional notes under the same indenture as the previously issued $750,000,000 aggregate principal amount of its 6.250% Senior Notes due 2034 and will be t ...

Core Viewpoint - A class action lawsuit has been filed against bluebird bio, Inc. regarding allegations of securities fraud and unlawful business practices [1] Group 1: Company Developments - On December 8, 2023, bluebird received FDA approval for its drug Lyfgenia (lovotibeglogene autotemcel) for treating sickle cell disease in patients aged 12 and older, but the approval included a black box warning for hematological malignancies due to two patients developing acute myeloid leukemia during clinical trials [2] - Following the announcement of the black box warning, bluebird's stock price dropped by $1.95 per share, or 40.54%, closing at $2.86 per share on the same day [2] Group 2: Legal Context - The class action lawsuit allows shareholders who purchased bluebird securities during the Class Period to request to be appointed as Lead Plaintiff by May 28, 2024 [1] - Pomerantz LLP, the firm handling the lawsuit, is recognized for its expertise in corporate, securities, and antitrust class litigation, having recovered billions in damages for class members over its 85-year history [3]

NEW YORK, May 21, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE).Shareholders who purchased shares of BLUE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/bluebird-bio-loss-submission-form/?id=80713&from=4CLASS PERIOD: April 24, 2023 to Decem ...

LOS ANGELES, May 16, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE).Class Period: April 24, 2023 – December 8, 2023Lead Plaintiff Deadline: May 28, 2024If you wish to serve as lead plaintiff of the bluebird lawsuit, you can submit your contact information at www.glancylaw.com/cases/bluebird-bio-Inc-1/. You can al ...

It won't be easy for the company to bounce back.Being a highly innovative company isn't a sufficient condition for success in the biotech industry. Bluebird Bio (BLUE), a small-cap gene-editing specialist, is a good example of this. Though the company has developed groundbreaking therapies, the stock has significantly lagged the market in recent years. Still, if Bluebird Bio can turn things around, the company could deliver explosive returns to investors who initiate a position today. Is Bluebird Bio worth ...

Financial Data and Key Metrics - Total revenue for Q1 2024 was $18.6 million, driven by ZYNTEGLO [13] - Cash on hand as of March 31, 2024, was $264 million, including $52 million in restricted cash [13] - The company anticipates gross to net discounts in the range of 20% to 25% for 2024 [13] - Cash runway is projected through Q1 2026, assuming the receipt of $50 million from the term loan facility [13] Business Line Data and Key Metrics - LYFGENIA achieved its first commercial patient start, marking a significant milestone [5] - ZYNTEGLO saw 11 patient starts since the beginning of 2024, with strong linear growth [9] - SKYSONA completed 3 patient starts since the beginning of 2024 [9] - The company expects between 85 and 105 patient starts across its commercial portfolio in 2024 [9] Market Data and Key Metrics - 64 qualified treatment centers (QTCs) have been activated for LYFGENIA and ZYNTEGLO [11] - More than half of the LYFGENIA QTCs are actively evaluating patients for gene therapy initiation [8] - 11 QTCs have started their first patient for one of the company's products, with many starting their second or third [11] Company Strategy and Industry Competition - The company is focused on establishing a robust network of QTCs, ensuring timely access to therapies, and optimizing the patient and provider experience [7] - The cost-effectiveness model for LYFGENIA was peer-reviewed and published, supporting its value proposition [10] - The company is not currently focused on ex-US markets but may consider partnerships in the future [53] Management Commentary on Operating Environment and Future Outlook - Management is optimistic about the momentum building for LYFGENIA, with the majority of patient starts expected in the second half of 2024 [8] - The company is confident in achieving its 2024 patient start guidance of 85 to 105, with a ramp-up expected in the latter half of the year [59] Other Important Information - The company is working on a restatement of its financials, which is not expected to impact cash position or revenue [13] - Manufacturing capacity for LYFGENIA is robust, with the ability to increase supply as demand grows [51] Q&A Session Summary Question: Medicaid reimbursement and its impact on patient starts for LYFGENIA [16] - Medicaid is not a rate-limiting factor, and patients can access therapy through medical exceptions if needed [19] Question: Study of LYFGENIA in younger patients [20] - A trial (HGB-210) is ongoing for pediatric patients aged 2 to 12, with completion expected by Q4 2024 [21] Question: Patient pull-through in the bluebird support system [22] - The company is not commenting on individual pull-through rates but notes strong patient interest and commitment to the treatment process [23] Question: QTC activity and patient choice between LYFGENIA and Casgevy [25] - Most QTCs are expected to offer both therapies, with patient choice being a key factor [26] Question: QTC activation and cell collection cycles [28] - 64 QTCs are activated, with about 50 receiving referrals for LYFGENIA [32] Question: Factors influencing the pace of patient starts [33] - Early adopters and patient readiness are key factors, with time being a significant component in the patient journey [34] Question: Definition of a new patient start [39] - A new patient start is defined by the completion of the first unique cell collection [40] Question: Financial trends and restatement impact [41] - The restatement will not impact cash or key metrics, but no further details on financial trends were provided [42] Question: Pace of cell collections for LYFGENIA [45] - The company expects an acceleration in patient starts, particularly in Q3 and Q4, with field teams focusing on patient pull-through [46] Question: Hydroxyurea washout and manufacturing capacity [47][50] - The company is not providing specific guidance on hydroxyurea washout but notes variability in patient readiness [49] - Manufacturing capacity for LYFGENIA is robust, with plans to increase supply as demand grows [51] Question: Ex-US market launch considerations [52] - The company is currently focused on the US market but may consider ex-US launches with a partner in the future [53] Question: Bottlenecks to patient starts and ZYNTEGLO treatment status [55] - Time is the primary factor, with medical readiness and insurance processes taking longer for sickle cell patients [56] Question: Confidence in achieving patient start guidance [58] - The company remains confident in achieving 85 to 105 patient starts in 2024, with momentum building in the second half of the year [59]